JP5822433B2 - ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体 - Google Patents

ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体 Download PDF

Info

Publication number
JP5822433B2
JP5822433B2 JP2009514365A JP2009514365A JP5822433B2 JP 5822433 B2 JP5822433 B2 JP 5822433B2 JP 2009514365 A JP2009514365 A JP 2009514365A JP 2009514365 A JP2009514365 A JP 2009514365A JP 5822433 B2 JP5822433 B2 JP 5822433B2
Authority
JP
Japan
Prior art keywords
cmv
pul128
pul130
complex
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009514365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539845A5 (https=
JP2009539845A (ja
Inventor
トーマス・シェンク
ダイ・ワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5822433(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Princeton University filed Critical Princeton University
Publication of JP2009539845A publication Critical patent/JP2009539845A/ja
Publication of JP2009539845A5 publication Critical patent/JP2009539845A5/ja
Application granted granted Critical
Publication of JP5822433B2 publication Critical patent/JP5822433B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2009514365A 2006-06-07 2007-06-06 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体 Active JP5822433B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81168906P 2006-06-07 2006-06-07
US60/811,689 2006-06-07
US90254407P 2007-02-20 2007-02-20
US60/902,544 2007-02-20
PCT/US2007/013365 WO2007146024A2 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013154361A Division JP6274770B2 (ja) 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Publications (3)

Publication Number Publication Date
JP2009539845A JP2009539845A (ja) 2009-11-19
JP2009539845A5 JP2009539845A5 (https=) 2010-06-17
JP5822433B2 true JP5822433B2 (ja) 2015-11-24

Family

ID=38832360

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009514365A Active JP5822433B2 (ja) 2006-06-07 2007-06-06 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2013154361A Active JP6274770B2 (ja) 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2015247487A Pending JP2016128418A (ja) 2006-06-07 2015-12-18 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013154361A Active JP6274770B2 (ja) 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2015247487A Pending JP2016128418A (ja) 2006-06-07 2015-12-18 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Country Status (5)

Country Link
US (5) US7704510B2 (https=)
EP (2) EP3031469B1 (https=)
JP (3) JP5822433B2 (https=)
CA (1) CA2654563A1 (https=)
WO (1) WO2007146024A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
CA2682700A1 (en) * 2007-05-11 2008-11-20 Vakzine Projekt Management Gmbh Composition containing hcmv particles
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
AU2009223688B2 (en) * 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
AU2013202396B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
PE20141435A1 (es) 2008-07-16 2014-10-22 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
EP2303923B1 (en) * 2008-07-16 2015-06-24 Institute for Research in Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
WO2011057124A1 (en) * 2009-11-06 2011-05-12 Transtarget, Inc. Polyclonal bispecific antibody compositions and method of use
WO2011076883A1 (en) 2009-12-23 2011-06-30 4-Antibody Ag Binding members for human cytomegalovirus
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
PT3970742T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
US20130164289A1 (en) * 2010-09-09 2013-06-27 Virginia Commonwealth University Human cytomegalovirus vaccine
WO2012047732A2 (en) * 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
JP2013544504A (ja) * 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
CA2825825A1 (en) * 2011-01-27 2012-08-02 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
WO2013054199A2 (en) * 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
KR20140138971A (ko) * 2012-03-28 2014-12-04 제넨테크, 인크. 항-hcmv 이디오타입 항체 및 이들의 용도
ES2753138T3 (es) 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Complejos de proteínas de citomegalovirus
DK2877580T3 (en) 2012-07-27 2019-04-23 Hope City VAT VACCINE TO DELIVER A UL128 COMPLEX AND PREVENT CMV INFECTION
EP2943221A1 (en) * 2013-01-10 2015-11-18 Novartis AG Influenza virus immunogenic compositions and uses thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US20150322115A1 (en) * 2014-05-08 2015-11-12 Redvax Gmbh Means and methods for treating cmv
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
US11572389B2 (en) * 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
CA3060019A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
KR20250006307A (ko) * 2017-09-13 2025-01-10 사노피 파스퇴르 인간 시토메갈로바이러스 면역원성 조성물
CN112512569A (zh) 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
CA3116175A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2020208082A1 (en) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
KR102837045B1 (ko) 2020-06-09 2025-07-23 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US20230293673A1 (en) * 2020-08-06 2023-09-21 La Jolla Institute For Immunology Methods for treating and preventing cytomegalovirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
TWI843471B (zh) * 2022-03-11 2024-05-21 財團法人國家衛生研究院 含抗原和dna之組成物及其用途
WO2025231404A1 (en) * 2024-05-03 2025-11-06 The Trustees Of Princeton University Telomerase inhibition for treating or inhibiting herpesvirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
AU2002247733B2 (en) * 2001-02-21 2007-12-13 The Wistar Institute Of Anatomy And Biology Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
DE10232322A1 (de) * 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
EP3031469B1 (en) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof

Also Published As

Publication number Publication date
EP2037959B1 (en) 2016-01-27
JP2013241442A (ja) 2013-12-05
EP3031469B1 (en) 2023-08-23
WO2007146024A2 (en) 2007-12-21
US7704510B2 (en) 2010-04-27
EP2037959A2 (en) 2009-03-25
US20140370026A1 (en) 2014-12-18
US20190358317A1 (en) 2019-11-28
CA2654563A1 (en) 2007-12-21
US8828399B2 (en) 2014-09-09
US20120226023A1 (en) 2012-09-06
EP3031469A1 (en) 2016-06-15
JP2016128418A (ja) 2016-07-14
US11129891B2 (en) 2021-09-28
JP2009539845A (ja) 2009-11-19
WO2007146024A3 (en) 2008-03-20
US20080187545A1 (en) 2008-08-07
JP6274770B2 (ja) 2018-02-07
US20110200633A1 (en) 2011-08-18
US8173362B2 (en) 2012-05-08

Similar Documents

Publication Publication Date Title
JP5822433B2 (ja) ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
Griffiths et al. Molecular biology and immunology of cytomegalovirus
Brunetti et al. Role of mannose-6-phosphate receptors in herpes simplex virus entry into cells and cell-to-cell transmission
Kropff et al. Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies
TWI570240B (zh) 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
CN102812043A (zh) 用于制备t细胞受体样单克隆抗体的方法及其用途
Giugni et al. Neutralization of human cytomegalovirus by human CD13-specific antibodies
US20240041994A1 (en) Cmv vaccine and method of making and using the same
CN116162154A (zh) 抗人巨细胞病毒抗体及其用途
Meng et al. Characterization of murine antibody responses to vaccinia virus envelope protein A14 reveals an immunodominant antigen lacking of effective neutralization targets
Le-Trilling et al. Maternal antibodies induced by a live attenuated vaccine protect neonatal mice from cytomegalovirus
US7147861B2 (en) Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate
CN113493495B (zh) Eb病毒balf4蛋白的抗原表位
Lane Murine Cytomegalovirus Enters Diverse Cell Types by the Novel Receptor Neuropilin-1
Horta Development of an indirect ELISA against Equine Herpesvirus Types 1 and 4
JPH0475583A (ja) ハイブリドーマ系細胞とその細胞により産生されるモノクローナル抗体
Karbach Protection from Cytomegalovirus Infection by Glycoprotein-specific Monoclonal Antibodies
Kropff et al. Glycoprotein N of Human Cytomegalovirus Protects the Virus from Neutralizing
WO2021108238A1 (en) Method for detecting cytomegalovirus (cmv) and measuring and quantifying pentameric complex using an indirect sandwich elisa
Gardner Development of human cytomegalovirus biologics as antiviral therapeutics
Pötzsch et al. B Cell Repertoire Analysis Identifies New Antigenic Domains on Glycoprotein B of
Herrman Neutralizing Antibodies to Epstein Barr Virus in the Rhesus Macaque Animal Model and in Humans
Wu Biochemical characterization of the major DNA-binding protein of murine cytomegalovirus
Sasaki Studies on MHC class I-mediated entry of equine herpesvirus-1 into cells
Lopper Molecular mechanisms of human cytomegalovirus entry

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130725

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130806

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140617

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150731

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151006

R150 Certificate of patent or registration of utility model

Ref document number: 5822433

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250